IL167900A - Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease - Google Patents

Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease

Info

Publication number
IL167900A
IL167900A IL167900A IL16790005A IL167900A IL 167900 A IL167900 A IL 167900A IL 167900 A IL167900 A IL 167900A IL 16790005 A IL16790005 A IL 16790005A IL 167900 A IL167900 A IL 167900A
Authority
IL
Israel
Prior art keywords
betamimetics
treatment
pharmaceutical compositions
chronic obstructive
obstructive pulmonary
Prior art date
Application number
IL167900A
Other languages
English (en)
Hebrew (he)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL167900(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of IL167900A publication Critical patent/IL167900A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL167900A 2002-11-15 2005-04-07 Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease IL167900A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
PCT/EP2003/012565 WO2004045618A2 (de) 2002-11-15 2003-11-11 Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung

Publications (1)

Publication Number Publication Date
IL167900A true IL167900A (en) 2013-06-27

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
IL167900A IL167900A (en) 2002-11-15 2005-04-07 Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease

Country Status (38)

Country Link
EP (2) EP2025338A1 (OSRAM)
JP (1) JP4317138B2 (OSRAM)
KR (1) KR101092247B1 (OSRAM)
CN (3) CN1713914A (OSRAM)
AR (2) AR041969A1 (OSRAM)
AT (1) ATE430569T1 (OSRAM)
AU (1) AU2003285326B2 (OSRAM)
BE (1) BE2014C016I2 (OSRAM)
BR (1) BRPI0316264B8 (OSRAM)
CA (1) CA2506082C (OSRAM)
CO (1) CO5570670A2 (OSRAM)
CY (2) CY1110500T1 (OSRAM)
DE (2) DE10253282A1 (OSRAM)
DK (1) DK1562603T3 (OSRAM)
EA (1) EA008665B1 (OSRAM)
EC (1) ECSP055774A (OSRAM)
ES (1) ES2326878T7 (OSRAM)
FR (1) FR14C0049I2 (OSRAM)
HR (1) HRP20050432B1 (OSRAM)
HU (1) HUS1400011I1 (OSRAM)
IL (1) IL167900A (OSRAM)
LT (1) LTC1562603I2 (OSRAM)
LU (1) LU92433I2 (OSRAM)
ME (1) ME00354B (OSRAM)
MX (1) MXPA05005081A (OSRAM)
MY (1) MY136034A (OSRAM)
NL (1) NL300650I2 (OSRAM)
NO (2) NO334314B1 (OSRAM)
NZ (1) NZ540661A (OSRAM)
PE (1) PE20040694A1 (OSRAM)
PL (1) PL212238B1 (OSRAM)
PT (1) PT1562603E (OSRAM)
RS (1) RS51607B (OSRAM)
SI (1) SI1562603T1 (OSRAM)
TW (1) TWI343812B (OSRAM)
UA (1) UA81276C2 (OSRAM)
WO (1) WO2004045618A2 (OSRAM)
ZA (1) ZA200502246B (OSRAM)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
JP2007533683A (ja) 2004-04-22 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患治療用のベンゾオキサジン含有医薬組成物
JP2007537187A (ja) * 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) * 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
WO2007017670A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
CN101208316B (zh) 2005-08-15 2012-05-09 贝林格尔·英格海姆国际有限公司 制备β-模拟物的方法
US20070088030A1 (en) * 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
PT2532679T (pt) 2005-10-21 2017-07-18 Novartis Ag Anticorpos humanos contra il13 e utilizações terapêuticas
EP1948186A1 (en) * 2005-11-09 2008-07-30 Boehringer Ingelheim International Gmbh Aerosolformulation for inhalation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2642239A1 (en) * 2006-02-16 2007-08-23 Boehringer Ingelheim International Gmbh Drug combinations for the treatment of respiratory tract diseases
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
SI2013211T1 (sl) 2006-04-21 2012-07-31 Novartis Ag Purinski derivati za uporabo kot agonisti receptorja adenozina A A
EP2057152A1 (de) * 2006-08-07 2009-05-13 Boehringer Ingelheim International GmbH Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Pi3k 지질 키나제 억제제로서의 피라졸로피리미딘
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
HRP20110201T1 (hr) 2007-01-10 2011-08-31 Irm Llc Spojevi i sastavi kao inhibitori proteaze kanalizirane aktivacije
AR065017A1 (es) * 2007-01-25 2009-05-13 Boehringer Ingelheim Int Procedimiento para la preparacion de betamimeticos
ATE499363T1 (de) 2007-05-07 2011-03-15 Novartis Ag Organische verbindungen
WO2009074575A2 (en) 2007-12-10 2009-06-18 Novartis Ag Organic compounds
CN101910153B (zh) 2008-01-11 2014-01-22 诺华股份有限公司 作为激酶抑制剂的嘧啶类
MX2010013675A (es) 2008-06-10 2011-02-15 Novartis Ag Derivados de pirazina como bloqueadores del canal de sodio epitelial.
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
SI2379507T1 (sl) 2008-12-30 2014-02-28 Pulmagen Therapeutics (Inflammation) Limited Spojine sulfonamida za zdravljenje respiratornih motenj
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
MX363549B (es) * 2010-09-21 2019-03-26 Intekrin Therapeutics Inc Star Composiciones farmacéuticas sólidas antidiabéticas.
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
CN103492384B (zh) 2011-02-25 2016-05-11 诺华股份有限公司 作为trk抑制剂的化合物和组合物
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
EP2755967B1 (en) 2011-09-16 2015-10-21 Novartis AG Heterocyclic compounds for the treatment of cystic fibrosis
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP2834246B1 (en) 2012-04-03 2021-07-28 Novartis AG Combination products with tyrosine kinase inhibitors and their use
JP2015533131A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 咳を治療するためのベータ2−アドレナリン受容体作動薬
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
EP3134395B1 (en) 2014-04-24 2018-01-31 Novartis AG Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
MX2016013981A (es) 2014-04-24 2016-11-15 Novartis Ag Derivados de amino-piridina como inhibidores de fosfatidil-inositol-3-cinasa.
EA032075B1 (ru) 2014-04-24 2019-04-30 Новартис Аг Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CN107207510B (zh) 2014-07-31 2019-11-29 诺华股份有限公司 联合疗法
EP3551187B1 (en) 2016-12-12 2021-02-17 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
DK3558954T3 (da) 2016-12-20 2021-12-06 Inke Sa Forbedret proces til fremstilling af r-6-hydroxy-8-[1-hydroxy-2-[2-(4methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CA3139634A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
AR119819A1 (es) 2019-08-28 2022-01-12 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
CN115768404B (zh) * 2020-06-09 2024-11-08 广州谷森制药有限公司 含乌美溴铵和三苯乙酸维兰特罗的药物制剂
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
MXPA02010179A (es) * 2000-04-27 2003-04-25 Boehringer Ingelheim Pharma Nuevos betamimeticos de larga accion, procedimiento para su preparacion y su empleo como medicamentos.

Also Published As

Publication number Publication date
HUS1400011I1 (hu) 2022-02-28
TW200423943A (en) 2004-11-16
CN101817800A (zh) 2010-09-01
DK1562603T3 (da) 2009-09-07
DE50311502D1 (de) 2009-06-18
RS51607B (sr) 2011-08-31
NL300650I2 (nl) 2017-11-02
UA81276C2 (en) 2007-12-25
WO2004045618A2 (de) 2004-06-03
ES2326878T7 (es) 2014-03-11
HRP20050432A2 (en) 2006-06-30
MY136034A (en) 2008-07-31
DE10253282A1 (de) 2004-05-27
EP1562603B3 (de) 2014-01-08
ZA200502246B (en) 2006-01-25
BE2014C016I2 (OSRAM) 2023-03-07
AU2003285326B2 (en) 2009-06-04
BR0316264A (pt) 2005-10-11
RS20050361A (sr) 2007-04-10
JP2006508140A (ja) 2006-03-09
EP1562603B1 (de) 2009-05-06
FR14C0049I1 (OSRAM) 2014-08-08
FR14C0049I2 (fr) 2015-07-24
ATE430569T1 (de) 2009-05-15
MXPA05005081A (es) 2005-07-01
ES2326878T3 (es) 2009-10-21
CY2014032I2 (el) 2015-12-09
MEP53608A (en) 2011-05-10
CN1713914A (zh) 2005-12-28
CY1110500T1 (el) 2015-04-29
EP1562603A2 (de) 2005-08-17
LU92433I2 (fr) 2014-06-24
ECSP055774A (es) 2005-11-22
NZ540661A (en) 2007-12-21
AR041969A1 (es) 2005-06-01
ME00354B (me) 2011-10-10
WO2004045618A3 (de) 2004-09-30
NO2014005I1 (no) 2014-03-10
NO20052883L (no) 2005-06-14
AU2003285326A1 (en) 2004-06-15
CO5570670A2 (es) 2005-10-31
PL375270A1 (en) 2005-11-28
EA008665B1 (ru) 2007-06-29
NO334314B1 (no) 2014-02-03
AR087241A2 (es) 2014-03-12
PL212238B1 (pl) 2012-08-31
CY2014032I1 (el) 2015-12-09
CN101735166A (zh) 2010-06-16
KR20050075013A (ko) 2005-07-19
BRPI0316264B1 (pt) 2019-04-09
JP4317138B2 (ja) 2009-08-19
CA2506082A1 (en) 2004-06-03
PT1562603E (pt) 2009-06-18
PE20040694A1 (es) 2004-11-23
SI1562603T1 (sl) 2009-10-31
BRPI0316264B8 (pt) 2021-05-25
EP2025338A1 (de) 2009-02-18
CA2506082C (en) 2011-06-21
TWI343812B (en) 2011-06-21
KR101092247B1 (ko) 2011-12-12
HRP20050432B1 (en) 2012-01-31
EA200500715A1 (ru) 2005-12-29
LTC1562603I2 (lt) 2016-12-12

Similar Documents

Publication Publication Date Title
IL167900A (en) Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
GB0520751D0 (en) Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
IL173908A0 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
ZA200706868B (en) 4-Oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases
TWI369987B (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
ZA200701584B (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
IL190338A0 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
IL179906A0 (en) Novel hydantoin derivatives for the treatment of obstructive airway diseases
IL164896A (en) Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors
IL190652A0 (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
IL185300A0 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
AU2002356646A1 (en) Pharmaceutical compositions for the pulmonary delivery of aztreonam
HUP0102388A3 (en) Use of diazepinoindole derivatives for the preparation of pharmaceutical composition treating chronic obstructive pulmonary disease
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
IL163871A0 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
AU2003270202A8 (en) Pharmaceutical compositions useful for the treatment of cancers
HU0500145D0 (en) Composition for the treatment of oral diseases
ZA200607463B (en) New pharmaceutical compositions for the treatment of sexual disorders II
HK1086482A (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation

Legal Events

Date Code Title Description
FF Patent granted
EXTF Application for patent extension filed

Filing date: 20151112

PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: OLODATEROL (AS HYDROCHLORIDE

Extension date: 20271010

KB Patent renewed
EXTJ Intention to grant a patent extension

Free format text: PRODUCT NAME: OLODATEROL (AS HYDROCHLORIDE)

Extension date: 20270119

EXTG Extension of patent term granted

Extension date: 20270119